The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Five-year survival outcomes from CRES3T: S-1 plus cisplatin with concurrent radical-dose radiotherapy followed by surgery for superior sulcus tumor.
 
Kazuya Takamochi
Speakers' Bureau - AstraZeneca; Chugai Pharma; Covidien/Medtronic; Johnson & Johnson; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
 
Kenji Suzuki
No Relationships to Disclose
 
Morihito Okada
No Relationships to Disclose
 
Seiji Niho
No Relationships to Disclose
 
Satoshi Ishikura
No Relationships to Disclose
 
Shunsuke Oyamada
Honoraria - Chugai Pharma
 
Takuhiro Yamaguchi
Stock and Other Ownership Interests - STATCOM
Consulting or Advisory Role - 3H Medi Solution; Chugai Pharma; DAIICHI SANKYO COMPANY, LIMITED.; Eisai; EPS Corporation; Incyte; intellim; Japan Tobacco Inc; Kowa; Merck; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Public Health Research Foundation; Sonire Therapeutics
Research Funding - Cordis. (Inst); DAIICHI SANKYO COMPANY, LIMITED. (Inst); Kyowa Kirin Co., Ltd. (Inst); NTT DOCOMO, INC. (Inst); Otsuka (Inst); Solasia Pharma (Inst); TSUMURA & CO. (Inst)
 
Hirotoshi Horio
No Relationships to Disclose
 
Norihiko Ikeda
No Relationships to Disclose
 
Fumihiro Tanaka
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Ono Pharmaceutical
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Covidien/Medtronic; Intuitive Japan; Johnson & Johnson/Janssen; Kyowa Kirin International; Lilly Japan; MSD; Olympus Medical Systems; Ono Pharmaceutical; Pfizer; Stryker; Taiho Pharmaceutical; Takeda
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst)
 
Satoshi Shiono
Honoraria - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Covidien/Medtronic; CSL Behring; Ethicon/Johnson & Johnson; KM Biologics; MSD; Ono Pharmaceutical
 
Tomohiro Haruki
No Relationships to Disclose
 
Hidemi Suzuki
No Relationships to Disclose
 
Hiroyuki Ito
No Relationships to Disclose
 
Hidetaka Uramoto
No Relationships to Disclose
 
Norihito Okumura
No Relationships to Disclose
 
Masahiro Tsuboi
Honoraria - Amgen KK; AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi-Sankyo; Johnson & Johnson; Lilly Japan; Medtronic; MSD K.K; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; AstraZeneca Japan; Chugai Pharma; MiRXES; MSD; Novartis
Research Funding - AstraZeneca Japan (Inst); Bristol-Myers Squibb KK (Inst); Johnson & Johnson/Eticon (Inst); Merck (Inst); MiRXES (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Advanced Clinical Trial Chest Surgery Group (ACTG)
No Relationships to Disclose